X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, AbbVie strengthens its neuroscience pipeline, including Mitokinin's lead compound, MTK-458, a selective PINK1 activator, designed to address mitochondrial dysfunction and potentially first-in-class disease-modifying treatment for Parkinson's Disease.
Lead Product(s): MTK-458
Therapeutic Area: Neurology Product Name: MTK-458
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: $654.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition October 05, 2023
Details:
Under the terms of the agreement, Mitokinin will receive an upfront payment and will continue developing its PINK1 activator program of MTK-458 through completion of IND enabling studies for Mitokinin's lead compound.
Lead Product(s): MTK-458
Therapeutic Area: Neurology Product Name: MTK-458
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: AbbVie Inc
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement March 02, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
